Form 8K Kalaris Therapeutics Inc For: 11 August
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Kalaris Therapeutics Inc (KLRS)
Track today's live Kalaris Therapeutics (KLRS) share price, performance and key data on this page with our current NASDAQ:KLRS stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Kalaris Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the KLRS share price, head to our technical summary section, which provides analysis on Kalaris Therapeutics share price buy/sell indicators using real-time data (or discuss the Kalaris Therapeutics (KLRS) stock price today with other investors in the Kalaris Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:KLRS share price (ISIN: US4829291065) to enhance your trading decisions with our free investment tools and resources.
What Is the Kalaris Therapeutics Inc Share Price Today?
The Kalaris Therapeutics share price today is 4.0800.
What Is the Stock Symbol for Kalaris Therapeutics Inc
The stock symbol (or 'ticker') for Kalaris Therapeutics Inc is "KLRS."
What Stock Exchange Does Kalaris Therapeutics Inc Trade On?
Kalaris Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Kalaris Therapeutics Inc a Good Stock to Buy?
Determining whether Kalaris Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:KLRS share price (ISIN: US4829291065) to enhance your trading decisions with our free investment tools and resources.
What Is the Kalaris Therapeutics Inc Share Price Today?
The Kalaris Therapeutics share price today is 4.0800.
What Is the Stock Symbol for Kalaris Therapeutics Inc
The stock symbol (or 'ticker') for Kalaris Therapeutics Inc is "KLRS."
What Stock Exchange Does Kalaris Therapeutics Inc Trade On?
Kalaris Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Kalaris Therapeutics Inc a Good Stock to Buy?
Determining whether Kalaris Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.8800
4.1500
52 wk Range
2.3600
11.8800
KLRS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.88004.1500
52 wk Range
2.360011.8800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
KLRS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
18.7143
Upside
+358.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
Kalaris Therapeutics appoints Liisa Bayko as CFO- Investing.com
- Form 8K Kalaris Therapeutics Inc For: 11 August
- Investing.com
- Kalaris Therapeutics appoints Liisa Bayko as CFO
- Investing.com
Kalaris Therapeutics names Liisa Bayko as CFO- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 18.7143
(+358.68% Upside)
Earnings
Latest Release
11/08/2026
EPS / Forecast
-0.48 / -0.50
Revenue / Forecast
-- / --
Compare KLRS to Peers and Sector
Metrics to compare | KLRS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKLRSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −4.0x | −0.4x | |
PEG Ratio | −0.03 | −0.04 | 0.00 | |
Price/Book | 1.7x | 2.1x | 2.6x | |
Price / LTM Sales | - | 69.7x | 3.1x | |
Upside (Analyst Target) | 390.2% | 171.5% | 48.3% | |
Fair Value Upside | Unlock | 2.2% | 6.2% | Unlock |
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Kalaris Therapeutics (NASDAQ: KLRS) Share Price Today?
The Kalaris Therapeutics stock price today is 4.0800 USD.
What Stock Exchange Does Kalaris Therapeutics (KLRS) Trade On?
Kalaris Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Kalaris Therapeutics?
The stock symbol (also called a 'ticker') for Kalaris Therapeutics is "KLRS."
What Is the Current Kalaris Therapeutics Market Capitalisation?
As of today, Kalaris Therapeutics (NASDAQ: KLRS) market cap is 92.3100M USD.
What Is Kalaris Therapeutics's (KLRS) Earnings Per Share (TTM)?
The Kalaris Therapeutics EPS is currently -2.0646 (Trailing Twelve Months).
When Is the Next Kalaris Therapeutics Earnings Date?
Kalaris Therapeutics's next earnings report will be released on 18/11/2026.
Is KLRS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Kalaris Therapeutics moving averages and other technical indicators, the daily buy/sell signal for KLRS stock is Neutral.
How Many Times Has Kalaris Therapeutics Stock Split?
Kalaris Therapeutics has split 1 times. (See the KLRS stock split history page for full effective split date and price information.)
How Many Employees Does Kalaris Therapeutics Have?
Kalaris Therapeutics has 20 employees, based on their latest Companies House report.
What is the current trading status of Kalaris Therapeutics (NASDAQ: KLRS)?
As of 16/08/2026, Kalaris Therapeutics (KLRS) is trading at a share price of 4.0800 USD, with a previous close of 3.8800 USD. The stock has fluctuated within a day range of 3.8800 USD to 4.1500 USD, while its 52-week range spans from 2.3600 USD to 11.8800 USD.
What Is Kalaris Therapeutics (KLRS) Price Target According to Analysts?
The average 12-month price target for Kalaris Therapeutics is 18.7143 USD, with a high estimate of 25 USD and a low estimate of 7 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +358.68% Upside potential.
What Is the KLRS Premarket Price?
KLRS's last pre-market stock price is 4.1000 USD. The pre-market share volume is 230.0000, and the stock has decreased by 0.2200, or 5.6700%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.